Sirtex stock price at 10 times sales robust quarter sales of irradiated Y-90 microspheres
For those that can do their due diligence and accept risk to reward in this company. Take a look at Sirtex' stock price, now trading at 10 times sales, based on the robust sales of Yttrium-90 microspheres. We have a better product and they will be using radiogel down the line. We will get FDA approval. Look at the success of these. Read the Sydney Morning Herald Business. We have a better Y-90 product! In this quarter sales surged 27.1%. We will get FDA approval and show the world our product. It is a superior product. Please do your due diligence and if you can't see the potential, don't bash, go to another stock. This is the real deal, look at Sirtex' microspheres! 10 years of sales growth! Look at AMIC's Radiogel! The technology is a game changer, not yet, but it will be. Radiogel!
Sirtex usually achieves net profit margins of about 18% – 20%. A regular company could be operating with margins of anywhere between 2% and 10%, but when competition or a weak economy comes, that could be cut quickly. We have Y-90 Radiogel. AMIC is a 2 cent stock now but with the potential of this technology the risk to reward is unbeatable. Again, I am showing you Sirtex because it uses Yttrium-90 for all you naysayers and look at our science and the potential of the United States for many other cancers besides Liver Cancer in using Radiogel. Those that can't see the relationship to Sirtex then please don't invest and look at something else. Just showing you some success with Y-90 and medical isotopes. Don't bash, do your own due diligence.